Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
NCT00665457
Terminated
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving chemotherapy and celecoxib for stage II or stage III breast cancer that can be removed by surgery.
Gender:
FEMALE
Ages:
Between 19 years and 120 years
Trial Updated:
08/21/2023
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
NCT03329378
Terminated
Primary Objective: • Determination of pathologic complete response (pCR) rates Secondary Objective: * Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin. * Breast conservation rates * Overall survival Study Design * Approximately 34-74 patients with Her2 positive, Stage II-regional IV breast cancer will be enrolled. * Patients will be stratified by ER/PR status. * They will be randomized to ddACTHP vs TCHP. * Initially, 17 patients will... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Mount Sinai Beth Israel, New York, New York +2 locations
Conditions: Locally Advanced Breast Cancer
Register for Updates
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
NCT04029038
Withdrawn
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called "chimeric antigen receptors (CAR)" are transferred to the collected T-cel... Read More
Gender:
ALL
Ages:
Between 6 months and 70 years
Trial Updated:
08/16/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
Register for Updates
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
NCT00039130
Completed
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combinin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/16/2023
Locations: Naval Medical Center - San Diego, San Diego, California +30 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
NCT04119336
Terminated
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
NCT04227275
Terminated
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Moffitt Cancer Center, Tampa, Florida +8 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
NCT03338972
Completed
This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to caus... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/15/2023
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
NCT04093596
Active Not Recruiting
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +10 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
NCT00101101
Completed
RATIONALE: Vaccines made from gene-modified cells and a person's cancer cells may make the body build an effective immune response to kill cancer cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill cancer cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lymphoma
Register for Updates
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
NCT00006734
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy an... Read More
Gender:
ALL
Ages:
Between 0 years and 50 years
Trial Updated:
08/01/2023
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +238 locations
Conditions: Sarcoma
Register for Updates
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
NCT00146562
Completed
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +5 locations
Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Register for Updates
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT05266196
Enrolling By Invitation
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/31/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
Register for Updates